bluebird bio Inc (BLUE) Quote

https://www.businesswire.com/news/home/20240924257891/en/ ...🥳

yes,encouraging news it is. These 3 factors stand out for me from today's news,let's only hope these work out as planned:

Cash Flow Break-Even next year....anticipates approximately 40 patient starts in Q4 2024.....restructuring intended to optimize the Company’s cost structure

A raise and even an R/S will not be too bad.

This is encouraging, but still a raise Is necessary in q4:

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the
Second Half of 2025
Actions intended to reduce cash operating expenses by approximately 20%
Management team to host conference call today,
September 24 at 8:00 am ET
SOMERVILLE, Mass.-(BUSINESS WIRE) -- Sep. 24, 2024--Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025.
The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even target assumes scaling to approximately 40 drug product deliveries per quarter, realizing the 20% reduction in cash operating expenses, and obtaining additional cash resources to extend the Company's cash runway.

Another gene therapy treatment start for BLUE, this time for beta-thalassemia, another dreaded blood disorder. Looks like this article was published this evening around the time we had that spike in a/h. Wonder if this could have also been one reason for the A/H action?
https://www.detroitnews.com/story/news/local/michigan/2024/09/23/dmc-hospital-starts-new-gene-treatments-for-blood-disorders-sickle-cell-anemia/75346376007/

I assumed they must've filed the Q2 financials when I saw the pop,but I suppose that will also be coming soon. One thing at a time,go BLUE.

BLUE...52s clearing...Hit .74...Strong volume hitting here...🥳

Oh thanks for that piece sr, missed seeing it! I thought maybe they filed the June quarter financials.

BLUE............................https://stockcharts.com/h-sc/ui?s=BLUE&p=W&b=5&g=0&id=p86431144783

On September 20, 2024, bluebird bio, Inc. (the "Company") and Henogen SRL, a part of Thermo Fisher Scientific ("Henogen") entered into a Master Services Agreement for Viral Vector Services, effective as of September 15, 2024 (the "Henogen Agreement"). The Henogen Agreement replaces the Company's former manufacturing agreement with Henogen, which expired on September 15, 2024.
Pursuant to the Henogen Agreement, Henogen agrees to manufacture lentiviral vector ("LVV"), currently used in the Company's gene therapy product LYGENIA. Under the terms of the Henogen Agreement, Henogen is responsible for manufacturing LVV, conducting quality control, quality assurance, validation activities, stability testing, packaging and shipping, and providing related services for LVV for clinical or commercial use. The Henogen Agreement is structured so that individual project agreements may be entered into by the parties for the manufacture of a particular product. The Company has agreed to order LVV for commercial use based on a 12-quarter rolling forecast, subject to certain binding and semi-binding forecast periods.
The Henogen Agreement remains in effect until September 15, 2029, and will automatically renew for additional two-year periods unless either party provides advance notice of non-renewal. Either party may terminate the Henogen Agreement in the event of the other party's material uncured breach or bankruptcy proceedings, or due to certain force majeure events.
The Henogen Agreement contains certain representations, warranties, limitations of liabilities, confidentiality and indemnity obligations and other provisions customary for an agreement of its type.

BLUE (0.64) up 31% spiking in A/H,don't see any news,maybe they completed their filing dues?

BLUE...Big Blocks taking out 49s...🥳

That is as real as it gets...BLUE is doing great things...🥳https://www.nytimes.com/2024/09/16/health/sickle-cell-gene-therapy-kendric-cromer.html?unlocked_article_code=1.Mk4.G6Jx.YEbBz53pCfq5&smid=url-share

This article will be of interest for believers in sickle cell gene therapy & BLUE.Hoping for that kids treatment to be a success,even if our investment in the company doesn't pan out. Money can always be made elsewhere, but relief from this horrible disease will be huge.
https://www.nytimes.com/2024/09/16/health/sickle-cell-gene-therapy-kendric-cromer.html?unlocked_article_code=1.Mk4.G6Jx.YEbBz53pCfq5&smid=url-share

Have a Great Weekend Y'all...🥳

BLUE new 52 week low

Im going to be one hundred percent transparent here. I bought in at .70 and it didnt pan out. I now know why. In my experience this will trend lower until a market valuation reflects the future of the company.

I've said it before - as recently as October of 2023, the Bluebird website had "multiple undisclosed" featured on their pipeline page.

October 1 2023, 11:56:07

https://web.archive.org/web/20231001115607/https://www.bluebirdbio.com/our-science/pipeline

Key being, if they can get their sh*t together….

I doubt it unless B.o.D does something about the following payouts:

2023 salaries:
Andrew Obenshain
C.E.O-$682k(+awards, etc.~$3mm)
Thomas J. Klima
C.Commercial & O.O-$643k(+ etc~1.8mm)
Richard A. Colvin
Chief Medical Officer-$480k(+etc~1.3mm)

Basically, SG&A too high for new commercial launched pipeline!! Blue has been piggy bank for C-Ste…

Even .20 to .30. Half of the current price. Some of these can turn it around if they get their shit together. If they have some decent product in the pipeline. And there is always trading the swings for those who can stomach it

Perhaps, but it’s More about when they price 20-30mm post split shares and the discount the bankers will demand..example:
Come 4th qtr( if sec approves Fins, and goes effective) —shares trade down to $.30-40 times 20=$6-8 post split..then market forces a 50% discount , and bankers price post split @Not available for adoption with warrants attached…major dilution unfortunately!!
So, I’ll be waiting to it goes Effective by December ( tax loss selling will pick up prior to offering)

Maybe the R/S is that large because they expect the stock price to deteriorate between now and November?

BLUE new 52 week low

why?

BLUE new 52 week low

added BLUE also,tad below 0.50!

BLUE...Loading the 50s dip...🥳

Expected, but didn’t think 1:20
Will be voting NO( against) every proposal except for E&Y….Andrew and crew are crooks but they do have 3 valid fda approved drugs and therefore will continue to hold/add especially if B.o.D fires the thieves!!! Vote NO !!!!!!

This was expected I guess.Hoping this is the last of the negative news.Good luck to all

Thanks…I will hold and add dips…🥳

BLUE. Heads up.....
http://archive.fast-edgar.com/20240916/A422522CZ22Z52G2222H22Y2N2IATZ224262/
•To approve amendments to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio ranging from any whole number between 1-for-15 and 1-for-20, as determined by our Board of Directors in its discretion ("Proposal 4");

•To approve an amendment and restatement of the Company's 2023 Incentive Award Plan to, among other things, increase the number of shares of our common stock authorized for issuance thereunder ("Proposal 5");

In @ .578

If the concept of DEIB is not in accordance with business objectives of BLUE, then the entirety of the companies goals are irrelevant and meaningless.

It's been a downhill slide. Bluebird has a noble objective, but management is out to lunch on page 26 of the Annual Report:
"We believe Diversity, Equity, Inclusion and Belonging ("DEIB") are the cornerstone to an engaged, successful, and innovative organization. We are committed
to taking action to help address racial injustice and inequality. We established our DEIB steering committee that includes employees at all levels to provide oversight and guidance to establishing meaningful measures and actions to continue to increase DEIB at all levels and experiences. With significant input from employees and leaders at bluebird, we have adopted corporate goals to increase diversity and representation across our employee population."

BLUE...625...Little volume in the P/M...🥳...

georgie18

Member Level
Re: None

Sunday, September 15, 2024 11:22:52 AM

Post#
657739
of 657766
BLUE...606... https://schrts.co/kdIEvYpT ...🥳...Downtrend followed by a weekly reversal green candle...last two times this lead to a nice upside...

thanks for that info.

They said cash runway thru q1, 2025 and the way they burn*, 💯 positive of a raise as soon as SEC reviews Financials most likely..clock it back and do simultaneous offering .. they also want to access final tranches of Hercules**

*Material and Other Risks Associated with Our Business—
Below is a summary of the material risks to our business, operations and the investment in our common stock. This summary does not address all of the risks that we face:
• We have incurred significant losses since our inception and we may not achieve our goal of becoming profitable in the timeframe we expect, or at all.
• There is substantial doubt regarding our ability to continue as a going concern. We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our commercial programs, product development efforts or other operations.
• Among other potential adverse events, insertional oncogenesis is a significant risk of gene therapies using viral vectors that can integrate into the genome. Any such adverse events may require us to halt or delay further clinical development of our products or any future product candidates or to suspend or cease commercialization, and the commercial potential of our products and any such future product candidates may be materially and negatively impacted.
• We rely on complex, single-source supply chains for SKYSONA, ZYNTEGLO, and LYFGENIA, respectively. The manufacture, testing and delivery of LVV and drug products present significant challenges for us, and we may not be able to produce our vector and drug products at the quality, quantities, or timing needed to support our clinical programs and commercialization.

**The Loan and Security Agreement ("LSA") requires the Company to comply with customary affirmative and negative covenants, including, among other things, a requirement to deliver annual financial statements within 90 days of each fiscal year and quarterly financial statements within 45 days of each fiscal quarter. A failure to comply with these covenants, or failure to obtain a waiver for any non-compliance, would result in an event of default under the LSA and would allow Hercules to accelerate repayment of the debt, which could materially and adversely affect the business, results of operations and financial condition of the Company. On April 30, 2024, July 9, 2024, August 13, 2024, and August 29, 2024 the Company and Hercules entered into amendments to the LSA providing for revised monthly financial reporting metrics for each month through September 30, 2024 and extension of the deadlines by which the Company must provide certain annual and quarterly financial statements.
On August 13, 2024, the Company and Hercules entered into a third amendment to the LSA (the "Third Amendment"), pursuant to which the parties agreed to, among other things, revised terms for the availability of the second and third tranches of funding under the LSA. In accordance with the Third Amendment, the Company may draw the second tranche of $25.0 million during the period commencing on the date the Company has (x) received at least $75.0 million in gross cash proceeds from qualified financing transactions by December 20, 2024 and (y) completed patient starts (cell collections) for at least
50 LYFGENIA patients by March 31, 2025 or 70 LYFGENIA patients by June 30, 2025 (collectively, the "Tranche 2 Milestone") and ending on the earlier of
(i) the date that is 30 days immediately following achievement of the Tranche 2 Milestone and ii) July 31, 2025. The Company may draw the third tranche of $25.0 million during the period commencing on the date the Company has (x) received at least $100.0 million in gross cash proceeds from qualified financing transactions by December 20, 2024 or at least $125.0 million by June 30, 2025 and (y) completed 70 drug product deliveries within a given six-month period ending no later than December 31, 2025, at least 40 of which are for LYFGENIA (collectively, the "Tranche 3 Milestone") and ending on the earlier of (i) the date that is 30 days immediately following the date the Company achieves the Tranche 3 Milestone and (ii) December 31, 2025. Additionally, the Company and Hercules agreed to increase the minimum cash coverage requirement from 40% to 45% of the outstanding principal of the term loan.

I realize these are ‘safe harbor’ jargon statements, however a raise is needed is necessary before year end :(

They had 200+ million cash(end of Q1 2024),they had raised cash $125 million last Dec 2023 after Lfygenia was approved. Do you think BLUE will need to raise capital again?

BLUE...606... https://schrts.co/kdIEvYpT ...🥳...Downtrend followed by a weekly reversal green candle...last two times this lead to a nice upside...

didn't have much action in A/H though. They should've released this news on monday morning instead of late friday.Let's see what BLUE does monday.Good luck to us.

The most recent Wainwright conf, Andrew explained the long delay at length which I was pleased with and finally we can understand what happened…however, although a bull on the Bird, the salaries (and SG&A in general) needs to be reigned in so the next capital raise* won’t be as dilutive as anticipated..now that these restatements are filed( and soon the recent 2Q’s), blue will clock the current share structure back by at least 5, maybe 10 to 1 and simultaneously do a $100mm raise..

*currently 190mm O/S
Reverse by 10 or 5 allows the shares to trade @ $6/3 and they will do offering of 20mm shares or 40mm( approx $100mm cap raise needed for 2nd tranche from Hercules)

Then I will add more shares after major dilution— GLTA

Nice A/H news…🥳

Finally! BLUE completed the restatement of its consolidated financial statements for the year ended December 31, 2022. Hopefully now we get back on track.
https://finance.yahoo.com/news/bluebird-bio-announces-completion-restatement-204100078.html

I was starting to believe the 10Q and 10K weren't going to happen. But they did. Patiently waiting on the 10Q for 2024 Q2.

https://investor.bluebirdbio.com/sec-filings/sec-filing/10-k/0001293971-24-000037
https://investor.bluebirdbio.com/sec-filings/sec-filing/10-q/0001293971-24-000040

I still say BLUE was shot in the face by the FDA w the BB warning, AND that the SEC should investigate. Based on the trades over the last few weeks, I'm still bullish - but defeated enough that I cannot in good faith post that green bull.

Be easy, Bluebirds.

Have a Great Weekend Y'all...🥳

BLUE...6137...Break/Hold .63 and she will go ...🥳...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 383435

Thursday, September 12, 2024 9:47:50 AM

Post#
383482
of 383537
BLUE...59s clearing here...🥳

BLUE...59s clearing here...🥳

BLUE...5944...🥳

BLUE...5749...Trying Red to Green here...🥳

BLUE...551...Adding here...🥳

BLUE new 52 week low